original ) (raw )Ritonavir-boosted lopinavir as maintenance monotherapy in HIV-infected patients who achieved viral suppression during a second-line protease inhibitor-based regimen: a pilot randomized trial (BIDI-MONO)
Wisit Prasithsirikul
J Int Assoc Provid AIDS Care
View PDFchevron_right
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study
Warangkana Munsakul
Antiviral Therapy, 2012
View PDFchevron_right
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice
Paola Corsi
Journal of Medical Virology, 2010
View PDFchevron_right
Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study
Sara Melzi
Journal of Antimicrobial Chemotherapy, 2003
View PDFchevron_right
Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings
Wendy Stevens
AIDS, 2012
View PDFchevron_right
Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial
Roland Landman
Journal of Antimicrobial Chemotherapy, 2010
View PDFchevron_right
HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial
Alash'Le Abimiku
Journal of the International Association of Providers of AIDS Care (JIAPAC), 2019
View PDFchevron_right
Treatment with Lopinavir/Ritonavir in Heavily Pretreated Subjects Failing Multiple Antiretroviral Regimens in Clinical Practice
Paola Corsi
Journal of Acquired Immune Deficiency Syndromes, 2002
View PDFchevron_right
Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors
Sasisopin Kiertiburanakul , Ploenchan Chetchotisakd
HIV Medicine, 2007
View PDFchevron_right
Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital*
Mervyn Tyrer
Hiv Medicine, 2007
View PDFchevron_right
Lopinavir-Ritonavir Monotherapy Versus Lopinavir-Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week Analysis
Arazo P , Hernando Knobel , Joaquin Portilla
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
View PDFchevron_right
Response of HIV positive patients to the long-term salvage therapy by lopinavir/ritonavir
Jan Konvalinka
Journal of Clinical Virology, 2005
View PDFchevron_right
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial
Pedro Cahn
The Lancet Infectious Diseases, 2014
View PDFchevron_right
Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART
Paola Meraviglia
Journal of Antimicrobial Chemotherapy, 2005
View PDFchevron_right
A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial
Jan Gerstoft
Antiviral therapy, 2005
View PDFchevron_right
Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)
Roland Landman
Journal of Antimicrobial Chemotherapy, 2018
View PDFchevron_right
Lopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil
Monica Bay , Eduardo Sprinz
HIV Medicine, 2008
View PDFchevron_right
Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients
Eva Van Den Eynde
Journal of Antimicrobial Chemotherapy, 2012
View PDFchevron_right
A Multicenter, Open Labeled, Randomized, Phase III Study Comparing Lopinavir/Ritonavir Plus Atazanavir to Lopinavir/Ritonavir Plus Zidovudine and Lamivudine in Naive HIV-1-Infected Patients: 48-Week Analysis of the LORAN Trial
Bernd Salzberger
The open AIDS journal, 2011
View PDFchevron_right
Once‐Daily versus Twice‐Daily Lopinavir/Ritonavir in Antiretroviral‐Naive HIV‐Positive Patients: A 48‐Week Randomized Clinical Trial
Donna Mildvan
The Journal of Infectious Diseases, 2004
View PDFchevron_right
Lopinavir/ritonavir Monotherapy As Second-line Antiretroviral Treatment in Resource-limited Settings - Week 104 Analysis of ACTG A5230
David Katzenstein , Wendy Stevens
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015
View PDFchevron_right
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-infe...
Marcelo H Losso
The Lancet, 2013
View PDFchevron_right
Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure
Sasisopin Kiertiburanakul
AIDS Research and Therapy, 2009
View PDFchevron_right
Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study)
E. Mortier , David Zucman
Journal of Clinical Virology, 2010
View PDFchevron_right
Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy in the PIVOT trial
Alejandro Arenas-Pinto
AIDS (London, England), 2016
View PDFchevron_right
Lopinavir Plasma Concentrations and Virological Outcome with Lopinavir-Ritonavir Monotherapy in HIV-1-Infected Patients
Pompeyo Viciana
Antimicrobial Agents and Chemotherapy, 2013
View PDFchevron_right
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96
Gene Snyder
Antiviral Therapy, 2009
View PDFchevron_right
Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study)
Benedetto Celesia
The new microbiologica, 2016
View PDFchevron_right